Efficacy and Safety of a New Basal Insulin with a Bolus Boost (IDegAsp) Used Once Daily in Combination with Insulin Aspart (IAsp) in People with Type 1 Diabetes

被引：0
|
作者：
Hirsch, Irl B.
Franek, Edward
Courreges, Jean-Pierre
Mersebach, Henriette
Dykiel, Patrik
Bode, Bruce W.
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1064-P
引用
收藏
页码：A292 / A292
页数：1
相关论文
共 50 条
  • [1] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, used once daily in basal-bolus treatment with insulin aspart in type 1 diabetes
    Hirsch, I.
    Franek, E.
    Courreges, J. P.
    Mersebach, H.
    Dykiel, P.
    Bode, B. W.
    [J]. DIABETOLOGIA, 2011, 54 : S427 - S427
  • [2] Use of a New Basal Insulin with a Bolus Boost (IDegAsp) in Type 2 Diabetes: Comparison with Biphasic Insulin Aspart 30 (BIAsp 30)
    Vaag, Allan
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine V.
    Niskanen, Leo
    [J]. DIABETES, 2011, 60 : A313 - A313
  • [3] Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1)
    Hirsch, I. B.
    Franek, E.
    Mersebach, H.
    Bardtrum, L.
    Hermansen, K.
    [J]. DIABETIC MEDICINE, 2017, 34 (02) : 167 - 173
  • [4] Long-term efficacy and safety of insulin degludec in combination with bolus insulin aspart in children and adolescents with type 1 diabetes
    Thalange, N.
    Deeb, L. C.
    Iotova, V.
    Kawamura, T.
    Klingensmith, G. J.
    Philotheou, A.
    Silverstein, J.
    Tumini, S.
    Francisco, A. Ocampo
    Kinduryte, O.
    Danne, T.
    [J]. DIABETOLOGIA, 2014, 57 : S395 - S395
  • [5] Once-daily use of a new generation ultra-long acting basal insulin with a bolus boost in insulin-naive people with type 2 diabetes: comparison with insulin glargine
    Cuddihy, R.
    Tack, C. J.
    Heise, T.
    Davidson, J.
    Gouet, D.
    Liebl, A.
    Romero, E.
    Mersebach, H.
    Dykiel, P.
    Jorde, R.
    [J]. DIABETOLOGIA, 2010, 53
  • [6] Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal–Bolus): Exploratory Randomized Trial in Type 2 Diabetes
    Wan Mohamaed Wan Bebakar
    Louis Chaykin
    Malene Lundgren Hersløv
    Søren Rasmussen
    [J]. Diabetes Therapy, 2017, 8 : 197 - 205
  • [7] Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis
    Edina, Brenda C.
    Tandaju, Jeremy R.
    Wiyono, Lowilius
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [8] Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes
    Bebakar, Wan Mohamaed Wan
    Chaykin, Louis
    Herslov, Malene Lundgren
    Rasmussen, Soren
    [J]. DIABETES THERAPY, 2017, 8 (01) : 197 - 205
  • [9] Safety and efficacy of insulin aspart vs. regular human insulin in basal/bolus therapy for patients with gestational diabetes
    Jovanovic, L
    Howard, C
    Pettitt, D
    Zisser, H
    Ospina, P
    [J]. DIABETES, 2005, 54 : A675 - A675
  • [10] Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
    Thalange, Nandu
    Deeb, Larry
    Iotova, Violeta
    Kawamura, Tomoyuki
    Klingensmith, Georgeanna
    Philotheou, Areti
    Silverstein, Janet
    Tumini, Stefano
    Ocampo Francisco, Ann-Marie
    Kinduryte, Ona
    Danne, Thomas
    [J]. PEDIATRIC DIABETES, 2015, 16 (03) : 164 - 176
12345